Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | CD44 | P16070 | 2/20 | 0.53 |
| ▸ | PNMT | P11086 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593053 | 0.85 | NOS3 (0.56) | NOS3NOS1NOS2CD44PNMT | |
| SCHEMBL19153131 | 0.78 | CD44 (0.44) | CD44PNMTMAOBCHRNB2CHRNA4 | |
| SCHEMBL16784815 | 0.78 | CD44 (0.44) | CD44PNMTMAOBCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15269387 | 0.76 | CD44 (0.43) | CD44PNMTMAOBCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL31130678 | 0.76 | CD44 (0.43) | CD44PNMTMAOBCHRNB2CHRNA4 | |
| SCHEMBL18237416 | 0.74 | CD44 (0.41) | CD44PNMTMAOBCHRNB2CHRNA4 | |
| SCHEMBL20445879 | 0.74 | CD44 (0.41) | CD44PNMTMAOBCHRNB2CHRNA4 | |
| SCHEMBL22036589 | 0.74 | CD44 (0.41) | CD44PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1336895 | 0.73 | CD44 (0.40) | CD44PNMTMAOB | |
| Hydrochloric Acid SCHEMBL21980663 | 0.73 | CHRM3 (0.43) | CD44PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092554-A1 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | ENVIVO PHARMACEUTICALS, INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2009137503-A1 | HDAC INHIBITORS AND USES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137499-A1 | INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009067493-A2 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | NOS3 968/4885NOS1 1043/4885NOS2 1780/4885 |
| US-20110092554-A1 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | PSEN1, PSEN2, BACE1 | NOS3 1629/4885NOS1 2176/4885NOS2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.